Effect of 3 g of intravenous paracetamol on post‐operative analgesia, platelet function and liver enzymes in patients undergoing tonsillectomy under local anaesthesia

Silvanto, M.; Munsterhjelm, E.; Savolainen, Sauli; Tiainen, Pekka; Niemi, Tomi; Ylikorkala, Olavi; Scheinin, Harry; Olkkola, Klaus T.

doi:10.1111/j.1399-6576.2007.01376.x

Cited by 25 publications

(21 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GSH is the substrate of an enzymatic reaction catalyzed by GSTA1 (28); therefore, GSTA1 may theoretically reflect the degree of liver damage. In the APAP model, the protein content and mRNA expression of GSTA1 significantly decreased in accordance with previous predictions that GSTA1 is affected byAPAP-induced hepatic injury (29). The significant decrease of GSTA1 suggests that it maybe released as an antioxidant to protect the liver from various hepatotoxins.…”

Section: Discussionsupporting

confidence: 69%

Expression of glutathione S-transferase A1, a phase II drug-metabolizing enzyme in acute hepatic injury on mice

Liu

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. In the present study, three models of acute liver injury in mice were induced via the administration of CCl 4 (35 mg/kg, 24 h), acetyl-para-aminophenol (APAP; 200 mg/kg, 12 h) and ethanol (14 ml/kg, 8 h) to study the effect of glutathione S-transferase A1 (GSTA1) on acute liver injury. The serum levels of alanine transaminase, aspartate transaminase and liver homogenate indicators (superoxide dismutase, glutathione and glutathione peroxidase) were significantly lower in model groups compared with the control group (P<0.01), whereas the liver homogenate indicator malondialdehyde was significantly increased (P<0.01). The expression of GSTA1 in liver was significantly decreased in the model groups compared with the control group (P<0.01). GSTA1 protein content was 3.8, 1.3 and 2.6 times lower in the CCl 4, APAP and ethanol model groups, respectively. Furthermore, GSTA1 mRNA expression levels decreased by 4.9, 2.1 and 3.7 times in the CCl 4, APAP and ethanol model groups, respectively. Among the three models, the injury induced by CCl 4 was the most marked, followed by ethanol and finally APAP. These results suggest that GSTA1 may be released by the liver and serve as an antioxidant in the prevention of liver damage. IntroductionLiver disease poses a serious threat to human health and food safety, as consumption of animals with liver disease may be detrimental to health (1). Acute liver injury is the common pathway and initiating factor of many liver diseases, such as acute liver failure (2). Three models of liver injury are typically used in research as they are representational and reflect the situation of hepatotoxicity comprehensively and intuitively (3). CCl 4 is a classical hepatotoxicant, which is able to induce reactive oxygen formation and deplete glutathione (GSH) (4). Acetyl-para-aminophenol (APAP) hepatotoxicity is induced by the electrophile N-acetyl-p-benzoquinoneimine (NAPQI), which is able to induce mitochondrial dysfunction and oxidative stress, leading to liver damage (5). The major etiological factors of hepatotoxicity in ethanol-induced hepatic injury are oxidative stress and inflammatory responses (6). Due to the complexity of liver function and the diversity of liver damage factors, experimental animal models are not able to accurately and fully reflect the nature of liver injury (7). Furthermore, existing animal models have various limitations such as non-standardized methods, lack of reproducibility and non-unified methods (8).Glutathione S-transferases (GSTs) are enzymes that are able to protect cells from damage caused by reactive oxygen species (9). GSTA (α class GST) serves an important cytoprotective role in detoxifying reactive electrophiles and products of lipid peroxidation (10). GSTs including GSTA have previously been identified as inhibitors of stress-activated kinase activity, most notably c-Jun N-terminal kinase (11). This suggests that altered GST expression may be an important factor in modulating the cellular transition between proliferation, differentiation, and apo...

show abstract

Section: Discussionsupporting

confidence: 69%

Expression of glutathione S-transferase A1, a phase II drug-metabolizing enzyme in acute hepatic injury on mice

Liu

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…However, there are insufficient data for the use of intravenous paracetamol in migraine attacks. Intravenous acetaminophen differs from the available intravenous opioids and NSAIDs as it is not associated with the adverse effects (nausea and vomiting, and respiratory depression) seen after opioid use, or with platelet dysfunction, gastritis and renal toxicity that are related to NSAID use 8 9. Intravenous acetaminophen is rarely associated with hepatotoxicity, and has been shown to be safe even with underlying liver conditions.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, with the production of parenteral forms of non-steroidal anti-inflammatory drugs (NSAIDs), the analgesic efficacy of these drugs has become a topic of interest to researchers. In particular, an intravenous form of paracetamol has been introduced and, compared with other NSAIDs, is an effective drug in various types of pain7 8 with a wide safety margin and a low incidence of side effects.…”

Section: Introductionmentioning

confidence: 99%

Intravenous paracetamol versus dexketoprofen in acute migraine attack in the emergency department: a randomised clinical trial

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Five randomized, placebo‐controlled trials were identified; all compared intravenous acetaminophen with placebo . The benefit of intravenous acetaminophen over its comparator in pain control and opioid consumption was not consistent across the studies.…”

Section: Clinical Trialsmentioning

confidence: 99%

Clinical and Economic Evidence for Intravenous Acetaminophen

Yeh

Reddy

2012

Pharmacotherapy

View full text Add to dashboard Cite

Intravenous acetaminophen received United States Food and Drug Administration approval in November 2010 for the management of mild-to-moderate pain, management of moderate-to-severe pain with adjunctive opioid analgesics, and reduction of fever. Although intravenous acetaminophen generally improved pain relief and demonstrated opioid-sparing effects compared with placebo, it did not consistently reduce the frequency of opioid-related adverse events (e.g., postoperative nausea and vomiting). The safety and efficacy of intravenous acetaminophen as an antipyretic agent have been documented in adults and children; however, its cost is several-fold higher than that of the oral and rectal formulations. Although use of intravenous acetaminophen has reduced other postoperative resource utilization (e.g., hospital length of stay) in some studies outside the United States in patients undergoing abdominal surgery, a full economic evaluation in the United States has yet to be undertaken. In addition, its administration time (15-min infusion) and packaging (glass, single-use vial) have the potential to adversely affect patient flow in the postanesthesia care unit, create burden on patient care units, and lead to drug waste. Furthermore, 1 g of intravenous acetaminophen is formulated in 100 ml of solution, which may be an issue for patients with fluid restrictions. Given the clinical and economic evidence currently available, intravenous acetaminophen should not replace oral or rectal acetaminophen, but its use may be considered in a limited number of patients who cannot receive drugs orally and rectally and who cannot tolerate other parenteral nonopioid analgesic or antipyretic agents.

show abstract

Effect of 3 g of intravenous paracetamol on post‐operative analgesia, platelet function and liver enzymes in patients undergoing tonsillectomy under local anaesthesia

Cited by 25 publications

References 25 publications

Expression of glutathione S-transferase A1, a phase II drug-metabolizing enzyme in acute hepatic injury on mice

Expression of glutathione S-transferase A1, a phase II drug-metabolizing enzyme in acute hepatic injury on mice

Intravenous paracetamol versus dexketoprofen in acute migraine attack in the emergency department: a randomised clinical trial

Clinical and Economic Evidence for Intravenous Acetaminophen

Contact Info

Product

Resources

About